Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
AI Overview
This RFP seeks development of small-molecule antifungal compounds effective against resistant fungi like Candida auris and Aspergillus species. The goal is to address rising fungal infection rates and hospitalizations by creating safer, broad-spectrum alternatives to current treatments limited by toxicity and drug resistance.
This summary is AI-generated from the official solicitation.
Key Details
Official Description
Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in...
Change History
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Content updated: phase_1_description
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Close Date changed from 2026-04-22 to 2026-06-03
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Open Date changed from 2026-03-25 to 2026-05-06
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Status changed from Removed to Pre-Release
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Opportunity DHA26BZ01-DV005 no longer available
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
New opportunity: Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II)
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial